| 國立臺灣大學 |
2013 |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu, Shang-Ju; Tang, Jih-Luh; Lin, Chien-Ting; Kuo, Yuan-Yeh; Li, Li-Yu; Tseng, Mei-Hsuan; Huang, Chi-Fei; Lai, Yen-Jun; Lee, Fen-Yu; Liu, Ming-Chih; Liu, Chia-Wen; Hou, Hsin-An; Chen, Chien-Yuan; Chou, Wen-Chien; Yao, Ming; Huang, Shang-Yi; Ko, Bor-Sheng; Tsay, Woei; Tien, Hwei-Fang; 蔡偉; 李玢玉; 姚明; 陳建源; 柯博升; 田蕙芬; 劉敏枝; 郭遠燁; 黃聖懿; 吳尚儒; 唐季祿; 周文堅; 侯信安 |
| 臺大學術典藏 |
2021-01-04T12:12:39Z |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu S.-J.; HWEI-FANG TIEN; Tsay W.; Ko B.-S.; Huang S.-Y.; Yao M.; Tang J.-L.; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Hou H.-A.; Chen C.-Y.; Chou W.-C. |
| 臺大學術典藏 |
2013 |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
SHANG-JU WU; Chou W.-C.; Chen C.-Y.; Hou H.-A.; Liu C.-W.; Liu M.-C.; Lee F.-Y.; Lai Y.-J.; Huang C.-F.; Tseng M.-H.; Li L.-Y.; Tang J.-L.; Lin C.-T.; Kuo Y.-Y.; Yao M.; Huang S.-Y.; Ko B.-S.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2013 |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Lin C.-T.; Wu S.-J.; Tang J.-L.; MING YAO; Chou W.-C.; Chen C.-Y.; Liu C.-W.; Hou H.-A.; Liu M.-C.; Lee F.-Y.; Lai Y.-J.; Huang C.-F.; Tseng M.-H.; Li L.-Y.; Kuo Y.-Y.; Tien H.-F.; Huang S.-Y.; Ko B.-S.; Tsay W. |
| 臺大學術典藏 |
2021-01-06T03:58:35Z |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu S.-J.; JIH-LUH TANG; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Yao M.; Huang S.-Y.; Ko B.-S.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2013 |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Tang J.-L.; Wu S.-J.; Ko B.-S.; Tsay W.; Tien H.-F.; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Yao M.; SHANG-YI HUANG |
| 臺大學術典藏 |
2021-02-05T06:29:35Z |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu S.-J.;Tang J.-L.;Lin C.-T.;Kuo Y.-Y.;Li L.-Y.;Tseng M.-H.;Huang C.-F.;Lai Y.-J.;Lee F.-Y.;Liu M.-C.;Liu C.-W.;Hou H.-A.;Chen C.-Y.;Wen-Chien Chou;Yao M.;Huang S.-Y.;Ko B.-S.;Tsay W.;Tien H.-F.; Wu S.-J.; Tang J.-L.; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Hou H.-A.; Chen C.-Y.; WEN-CHIEN CHOU; Yao M.; Huang S.-Y.; Ko B.-S.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2022-01-12T07:07:35Z |
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
|
Wu S.-J.; Tang J.-L.; Lin C.-T.; Kuo Y.-Y.; Li L.-Y.; Tseng M.-H.; Huang C.-F.; Lai Y.-J.; Lee F.-Y.; Liu M.-C.; Liu C.-W.; HSIN-AN HOU; Chen C.-Y.; Chou W.-C.; Yao M.; Huang S.-Y.; Ko B.-S.; Tsay W.; Tien H.-F. |
| 臺大學術典藏 |
2018-09-10T04:06:49Z |
Clinical implications of using racemic drugs
|
Chen, C.-Y.;Shieh, W.-R.;Chen, C.-S.; CHING-YU CHEN |
| 國立臺灣大學 |
1992 |
Clinical Implications of Using Racemic Drugs
|
陳慶餘; 陳慶士; CHEN, CHING-YU; SHIEH, WOAN-RU; CHEN, CHING-SHIH |
| 中國醫藥大學 |
2010-06 |
Clinical Implications, Risk Factors and Mortality Following Community-onset Bacteremia Caused by Extended-spectrum β-lactamase (ESBL) and non-ESBL Producing Escherichia coli.
|
(Chia-Jung Hsieh); (Yea-Huei Shen); 黃高彬(Kao-Pin Hwang)* |
| 臺北醫學大學 |
2013 |
Clinical importance of angiogenic cytokines, fibrinolytic activity and effusion size in parapneumonic effusions
|
Chung, CL;Hsiao, SH;Hsiao, G;Sheu, JR;Chen, WL;SC」, 「Chang |
| 臺北醫學大學 |
2013 |
Clinical importance of angiogenic cytokines, fibrinolytic activity and effusion size in parapneumonic effusions
|
CL, Chung;SH, Hsiao;Hsiao, G;JR, Sheu;WL, Chen;SC」, 「Chang |
| 國立臺灣大學 |
2006 |
Clinical Improvement Following Home Parenteral Nutrition in Pediatric Patients with Intestinal Failure
|
童怡靖; 倪衍玄; 賴鴻緒; 謝德瑩; 張美惠; TUNG, YI-CHING; NI, YEN-HSUAN; LAI, HONG-SHIEE; HSIEH, DER-YIRNG; CHANG, MEI-HWEI |
| 臺大學術典藏 |
2006 |
Clinical improvement following home parenteral nutrition in pediatric patients with intestinal failure
|
Yen-Hsuan Ni; HONG-SHIEE LAI; MEI-HWEI CHANG; Tung, Y.-C. and Ni, Y.-H. and Lai, H.-S. and Hsieh, D.-Y. and Chang, M.-H. |
| 臺大學術典藏 |
2020-02-24T05:13:30Z |
Clinical improvement following home parenteral nutrition in pediatric patients with intestinal failure
|
Tung Y.-C.;Ni Y.-H.;Hong-Shiee Lai;Hsieh D.-Y.;Chang M.-H.; Tung Y.-C.; Ni Y.-H.; HONG-SHIEE LAI; Hsieh D.-Y.; Chang M.-H. |
| 臺大學術典藏 |
2020-12-28T08:14:47Z |
Clinical improvement following home parenteral nutrition in pediatric patients with intestinal failure
|
Tung Y.-C.;Yen-Hsuan Ni;Lai H.-S.;Hsieh D.-Y.;Chang M.-H.; Tung Y.-C.; YEN-HSUAN NI; Lai H.-S.; Hsieh D.-Y.; Chang M.-H. |
| 臺大學術典藏 |
2021-01-08T06:17:26Z |
Clinical improvement following home parenteral nutrition in pediatric patients with intestinal failure
|
Yi-Ching Tung;Ni Y.-H.;Lai H.-S.;Hsieh D.-Y.;Chang M.-H.; YI-CHING TUNG; Ni Y.-H.; Lai H.-S.; Hsieh D.-Y.; Chang M.-H. |
| 臺大學術典藏 |
2021-01-04T07:36:15Z |
Clinical improvement following home parenteral nutrition in pediatric patients with intestinal failure
|
Tung Y.-C.; Ni Y.-H.; Lai H.-S.; Hsieh D.-Y.; MEI-HWEI CHANG |
| 國立臺灣大學 |
2006-07 |
Clinical improvement following home parenteral nutrition in pediatric patients with intestinal failure.
|
Tung, YC; Ni, YH; Lai, HS; Hsieh, DY; Chang, MH. |
| 臺大學術典藏 |
2018-09-10T03:23:20Z |
Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients
|
Hu, R.-H. and Lee, P.-H. and Tsai, M.-K.; PO-HUANG LEE; MENG-KUN TSAI; REY-HENG HU |
| 國立臺灣大學 |
2000 |
Clinical Influencing Factors for Daily Dose, Trough Level, and Relative Clearance of Tacrolimus in Renal Transplant Recipients
|
李伯皇; LEE, PO-HUANG |
| 臺大學術典藏 |
2019-12-04T02:00:18Z |
Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients
|
Hu R.-H.;Lee P.-H.;Meng-Kun Tsai; Hu R.-H.; Lee P.-H.; MENG-KUN TSAI |
| 臺大學術典藏 |
2020-02-24T01:34:10Z |
Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients
|
Rey-Heng Hu;Lee P.-H.;Tsai M.-K.; REY-HENG HU; Lee P.-H.; Tsai M.-K. |
| 臺大學術典藏 |
2020-11-19T03:43:10Z |
Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients
|
Hu R.-H.;Po-Huang Lee;Tsai M.-K.; Hu R.-H.; PO-HUANG LEE; Tsai M.-K. |
